BMX Kinase

Bmx is a non-receptor tyrosine kinase belonging to the Tec kinase family. The protein contains a PH-like domain, which mediates membrane targeting by binding to phosphatidylinositol 3,4,5-triphosphate (PIP3), and a SH2 domain that binds to tyrosine-phosphorylated proteins and functions in signal transduction. The protein is implicated in several signal transduction pathways including the Stat pathway, and regulates differentiation and tumorigenicity of several types of cancer cells. Bmx is characterized by an N-terminal pleckstrin homology domain and has been shown to be a downstream effector of phosphatidylinositol 3-kinase. P21-activated kinase 1 (Pak1), another well characterized effector of phosphatidylinositol 3-kinase, has been implicated in the progression of breast cancer cells.

BMX Kinase Inhibitors

BMX-IN-1

(BMX kinase inhibitor) **Cat. No.:** HY-80002

BMX-IN-1 is a selective, irreversible inhibitor of **bone marrow tyrosine kinase on chromosome X (BMX)** that targets Cys^{496} in the BMX ATP binding domain with an IC_{50} of 8 nM, also targets the related Bruton's tyrosine kinase **(BTK)** with an IC_{50} value of 10.4 nM, but is more...



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

CHMFL-BMX-078

(CHMFL-BMX 078) **Cat. No.:** HY-101267

CHMFL-BMX-078 is a highly potent and selective type II irreversible **BMX** kinase inhibitor with an IC_{50} of 11 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with IC_{50}s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Poseltinib

(HM71224; LY3337641) **Cat. No.:** HY-109010

Poseltinib, an orally active, selective and irreversible **Bruton's tyrosine kinase (BTK)** inhibitor (IC_{50} =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively.



Purity: 98.01%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg